Related Experiment Video
Updated: Oct 11, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Dora Barbosa Rabago1, Collin M Blakely2, Franziska Haderk3
1Department of Medicine, University of California, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; Department of Cellular and Molecular Pharmacology, University of California, San Francisco.
Abstract:
Novel 3D cancer organoid cultures derived from clinical patient specimens represent an important model system to evaluate intratumor heterogeneity and treatment response to targeted inhibitors in cancer. Pioneering work in gastrointestinal and pancreatic cancers has highlighted the promise of patient-derived organoids (PDOs) as a patient-proximate culture system, with an increasing number of models emerging. Similarly, work in other cancer types has focused on establishing organoid models and optimizing culture protocols. Notably, 3D cancer organoid models maintain the genetic complexity of original tumor specimens and thus translate tumor-derived sequencing data into treatment with genetically informed targeted therapies in an experimental setting. Further, PDOs might foster the evaluation of rational combination treatments to overcome resistance-associated adaptation of tumors in the future. The latter focuses on intense research efforts in non-small-cell lung cancer (NSCLC), as resistance development ultimately limits the treatment success of targeted inhibitors. An early assessment of therapeutically targetable mechanisms using NSCLC PDOs could help inform rational combination treatments. This manuscript describes a standardized protocol for the cell culture plate-based assessment of drug sensitivities to targeted inhibitors in NSCLC-derived 3D PDOs, with potential adaptability to combinational treatments and other treatment modalities.
Insights
Patient-derived organoids (PDOs) offer a 3D cancer model to test targeted therapies. This study standardizes a protocol for assessing drug sensitivity in non-small-cell lung cancer PDOs, aiding future combination treatments.
Area of Science:
- Oncology
- Biotechnology
- Genomics
Background:
- 3D cancer organoid cultures from patient specimens are crucial for studying tumor heterogeneity and treatment response.
- Patient-derived organoids (PDOs) are emerging as promising patient-proximate models, particularly in gastrointestinal and pancreatic cancers.
- These models preserve the genetic complexity of tumors, enabling genetically informed targeted therapy evaluation.
Purpose of the Study:
- To establish a standardized protocol for assessing drug sensitivities to targeted inhibitors in 3D non-small-cell lung cancer (NSCLC) PDOs.
- To provide a platform for evaluating rational combination treatments to overcome drug resistance in NSCLC.
- To adapt existing organoid culture protocols for cell culture plate-based drug sensitivity assessments.
Main Methods:
- Development of a standardized protocol for 3D PDO culture.
- Application of the protocol for drug sensitivity assessment in cell culture plates.
- Focus on targeted inhibitors relevant to non-small-cell lung cancer.
Main Results:
- A standardized protocol for assessing drug sensitivities in NSCLC PDOs was successfully described.
- The protocol is suitable for cell culture plate-based drug screening.
- The methodology shows potential for adaptation to combinational treatments and other therapeutic modalities.
Conclusions:
- 3D NSCLC PDOs are valuable for evaluating targeted inhibitor responses and guiding treatment strategies.
- Standardized protocols are essential for reproducible drug sensitivity assessments in PDO models.
- This work provides a foundation for future research into personalized combination therapies for NSCLC.
